ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – VYGR
February 23, 2021 19:45 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
ROSEN, A LEADING LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
February 18, 2021 19:10 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
ROSEN, A LEADING AND RANKED FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
February 10, 2021 16:28 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
Voyager Therapeutics to Present at Upcoming Investor Conferences in October 2019
September 25, 2019 08:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics to Present at Upcoming Investor Conferences in September 2019
August 28, 2019 08:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics to Host Second Quarter 2019 Financial Results and Corporate Highlights Conference Call
August 05, 2019 16:30 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics to Present at Upcoming Investor Conferences in August 2019
July 30, 2019 16:30 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update
June 17, 2019 07:30 ET
|
Voyager Therapeutics, Inc.
Gains worldwide rights to VY-HTT01 for Huntington’s disease Resources to be reallocated to VY-HTT01 and other programs; intends to seek a partner for the SOD1 ALS program CAMBRIDGE, Mass., June 17,...
Voyager Therapeutics to Present at the Raymond James Life Sciences & MedTech Conference
June 11, 2019 16:30 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., June 11, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
March 28, 2019 16:15 ET
|
Voyager Therapeutics, Inc.
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of...